Vivero Matthew P, Chen Yu-Jen, Antunez Alexis G, Cho Nancy L, Nehs Matthew A, Doherty Gerard M, Bates David W, Liu Jason B
Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Gland Surg. 2024 Jul 30;13(7):1201-1213. doi: 10.21037/gs-24-128. Epub 2024 Jul 24.
Although primary hyperparathyroidism (PHPT) is readily diagnosed biochemically and can be cured with low-risk surgery, it is often underrecognized and undertreated. Our objectives were to characterize, within our health system, how often patients with hypercalcemia were evaluated for PHPT and how often patients with PHPT underwent definitive treatment with parathyroidectomy.
Ambulatory patients aged 18 years or older seen at our health system between January 2018 and June 2023 with chronic hypercalcemia were identified from the medical record. After excluding causes of secondary hyperparathyroidism, the proportion of patients with parathyroid hormone (PTH) tests was calculated. Among patients with biochemical evidence of PHPT, the proportion of patients who underwent parathyroidectomy was calculated. Multivariable logistic regression was used to identify factors associated with an evaluation for PHPT and, separately, with parathyroidectomy.
Of 7,675 patients with chronic hypercalcemia, 3,323 (43.3%) had a PTH test obtained within 6 months. An age between 40-49 <30 years [(odds ratio (OR) =3.2; 95% confidence interval (CI): 1.8-5.6; P<0.001], a serum calcium level between 11.6-12.0 <11.0 mg/dL (OR =3.9; 95% CI: 3.2-4.7; P<0.001), and osteoporosis (OR =3.1; 95% CI: 2.7-3.5; P<0.001) were associated with an evaluation for PHPT. Among those with PTH levels, 1,327 (39.9%) had PHPT but only 916 (69.0%) were recognized. Three hundred and forty-five (26.0%) patients with PHPT underwent parathyroidectomy. An increasing number of surgical indications was associated with parathyroidectomy (P<0.001), though overall rates remained less than 40%. Among indications for surgery, including age and serum total calcium level, only osteoporosis was associated with parathyroidectomy (OR =2.0; 95% CI: 1.4-2.8; P<0.001).
In this study, more than half of patients with chronic hypercalcemia were not evaluated for PHPT. Among patients with biochemical evidence of PHPT, one-third were unrecognized and only one-in-four received curative treatment. Opportunities to improve the management of PHPT exist within our large integrated health system.
尽管原发性甲状旁腺功能亢进症(PHPT)通过生化检查很容易诊断,并且可以通过低风险手术治愈,但它常常未得到充分认识和治疗。我们的目标是在我们的医疗系统中,确定高钙血症患者接受PHPT评估的频率以及PHPT患者接受甲状旁腺切除术进行确定性治疗的频率。
从病历中识别出2018年1月至2023年6月在我们医疗系统就诊的18岁及以上的门诊慢性高钙血症患者。排除继发性甲状旁腺功能亢进的病因后,计算进行甲状旁腺激素(PTH)检测的患者比例。在有PHPT生化证据的患者中,计算接受甲状旁腺切除术的患者比例。使用多变量逻辑回归来确定与PHPT评估相关的因素,以及分别与甲状旁腺切除术相关的因素。
在7675例慢性高钙血症患者中,3323例(43.3%)在6个月内进行了PTH检测。年龄在40 - 49岁之间、<30岁(比值比(OR)=3.2;95%置信区间(CI):1.8 - 5.6;P<0.001),血清钙水平在11.6 - 12.0、<11.0mg/dL(OR =3.9;95%CI:3.2 - 4.7;P<0.001),以及骨质疏松(OR =3.1;95%CI:2.7 - 3.5;P<0.001)与PHPT评估相关。在进行PTH检测的患者中,1327例(39.9%)患有PHPT,但只有916例(69.0%)被识别出来。345例(26.0%)PHPT患者接受了甲状旁腺切除术。手术指征数量增加与甲状旁腺切除术相关(P<0.001),尽管总体比例仍低于40%。在手术指征中,包括年龄和血清总钙水平,只有骨质疏松与甲状旁腺切除术相关(OR =2.0;95%CI:1.4 - 2.8;P<0.001)。
在本研究中,超过一半的慢性高钙血症患者未接受PHPT评估。在有PHPT生化证据的患者中,三分之一未被识别,只有四分之一接受了治愈性治疗。在我们庞大的综合医疗系统中存在改善PHPT管理的机会。